Immunic (NASDAQ:IMUX – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20), FiscalAI reports.
Immunic Stock Performance
Shares of NASDAQ IMUX traded down $0.27 during trading on Friday, hitting $7.52. The company had a trading volume of 105,145 shares, compared to its average volume of 283,926. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43. The business’s 50-day moving average is $8.70 and its 200 day moving average is $11.52. The company has a market cap of $102.57 million, a P/E ratio of -1.72 and a beta of 1.48.
Key Headlines Impacting Immunic
Here are a few of the latest headlines about IMUX:
- Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
- Neutral Sentiment: Immunic is preparing to start its Phase 3 PROTECT-MS trial for progressive MS, with first-patient enrollment expected in the first half of 2027. The company also announced leadership appointments intended to support regulatory and commercial readiness. Article: Immunic reports third-quarter 2026 financial results and provides corporate update
- Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
Analysts Set New Price Targets
IMUX has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Wall Street Zen cut Immunic from a “sell” rating to a “strong sell” rating in a research report on Saturday. Cantor Fitzgerald started coverage on Immunic in a report on Friday, October 23rd. They issued an “overweight” rating for the company. Roth Capital reaffirmed a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Immunic in a report on Thursday, September 10th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.43.
Get Our Latest Stock Analysis on Immunic
About Immunic
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.
Read More
- Five stocks we like better than Immunic
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
